Based on the award of a Royce Undergraduate Research Internship Scheme Emily has started a 10 week project to investigate how the robotic platforms in the Materials Innovation Factory can be used to accelerate research in the effect of washing conditions on the removal of found in recycled plastics. This work is in collaboration with Bright Green Plastics and offers the potential to lead to an improvements in the quality of recycled plastics.
The review article assocaited with Josh’s work with PZ Cussons has been published. Josh worked on on the KTP project Understanding the physiological processes of the DHA skin colouring mechanism.
Congratulations to former group PhD student Jess and Edyta who had their in person graduation ceremony recently. It was great to able to see them in-person and celebrate their success with them.
Cameron’s paper in Journal of Materials Chemistry B has been selected as one of the journal’s HOT papers for 2021. The list of the hot papers can be seen here.
Our 1st paper of 2022 comes from Dom’s research. In this paper, Dom shows how the thermoresponsive and degradation behaviour of nanogels can be tuned by using a core-shell structure.
We are really pleased to welcome Mazrina Mazlan to join our group. Mazrina’s PhD is going to be focussed on making degradable multi-responsive nanogels. Mazrina joins the group on a Malaysian scholarship.
Cameron’s first paper is now published. Cameron prepared hydrophobically modified drug analogues and used these to produce nanoparticles. These particles displayed high drug loading and the LogP of the compound controlled NP formation.
Congratulations to Jess who completed her viva July and completed her corrections in September. Jess’ PhD is focussed on designing nanoparticles for the deliver of therapeutics for the treatment of preterm birth. Jess leaves our group to join the Rannard group as a PhD.
Congratulations to Heba who completed her viva May and graduated earlier this month. Heba’s work is focussed on lipid-based nanoparticles for the delivery of HIV drugs. Her second paper is due to be submitted in the next month. We wish Heba all the best in the next stages of her career.